{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:42:35Z","timestamp":1758044555708,"version":"3.44.0"},"reference-count":88,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128181287"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/b978-0-12-818128-7.00013-7","type":"book-chapter","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T05:01:23Z","timestamp":1599195683000},"page":"287-303","source":"Crossref","is-referenced-by-count":2,"title":["3D in vitro cutaneous melanoma models"],"prefix":"10.1016","author":[{"given":"Ana I.","family":"Soares","sequence":"first","affiliation":[]},{"given":"Rui L.","family":"Reis","sequence":"additional","affiliation":[]},{"given":"Alexandra P.","family":"Marques","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib2","first-page":"S1","article-title":"Current and future roles of targeted therapy and immunotherapy in advanced melanoma","volume":"20","author":"Olszanski","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-019-0666-x","article-title":"Adjuvant therapy for melanoma","volume":"20","author":"Wada-Ohno","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","article-title":"Many ways to resistance: how melanoma cells evade targeted therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib6","first-page":"e1265","article-title":"Global incidence and mortality of skin cancer by histological subtype and its relationship with the human development index (HDI); an ecology study in 2018","volume":"6","author":"Khazaei","year":"2019","journal-title":"WCRJ"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib7","article-title":"Cancer facts & figures","author":"Fauci","year":"2016","journal-title":"Atlanta: American Cancer Society"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib9","doi-asserted-by":"crossref","first-page":"E1566","DOI":"10.3390\/ijms19061566","article-title":"Cutaneous melanoma\u2014a long road from experimental models to clinical outcome: a review","volume":"19","author":"Coricovac","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities","volume":"247","author":"Rabbie","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0046-8177(86)80032-6","article-title":"The biologic forms of malignant melanoma","volume":"17","author":"Clark","year":"1986","journal-title":"Hum Pathol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib13","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40257-017-0325-6","article-title":"Advanced melanoma: current treatment options, biomarkers, and future perspectives","volume":"19","author":"Rozeman","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hoc.2009.03.010","article-title":"Melanoma epidemiology","volume":"23","author":"Tucker","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/path.5039","article-title":"Ultraviolet light and melanoma","volume":"244","author":"Craig","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ijc.2910620402","article-title":"Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies","volume":"62","author":"Bliss","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1897-4287-2-3-123","article-title":"Familial malignant melanoma - overview","volume":"2","author":"D\u0119bniak","year":"2004","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pmedr.2015.11.016","article-title":"Tanning bed use and melanoma: establishing risk and improving prevention interventions","volume":"3","author":"Le Clair","year":"2016","journal-title":"Prev Med Rep"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1195-328","article-title":"Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans","volume":"11","author":"Valverde","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1747.1998.00357.x","article-title":"Pheo)melanin photosensitizes UVA-induced DNA damage in cultured human melanocytes","volume":"111","author":"Wenczl","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib23","doi-asserted-by":"crossref","first-page":"E2889","DOI":"10.3390\/ijms19102889","article-title":"The pro-oxidant activity of pheomelanin is significantly enhanced by UVA irradiation: benzothiazole moieties are more reactive than benzothiazine moieties","volume":"19","author":"Tanaka","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1039\/c1pp05133d","article-title":"Activation of p38 MAP kinase and JNK pathways by UVA irradiation","volume":"11","author":"Zhang","year":"2012","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib25","first-page":"164","article-title":"Assessment of ultraviolet (UV) radiation from technical sources","volume":"17","author":"Chady\u0161iene","year":"2009","journal-title":"J Env Eng Landsc Manag"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1039\/c1pp05190c","article-title":"DNA damage spectra induced by photosensitization","volume":"11","author":"Epe","year":"2012","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib27","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1039\/c3pp50023c","article-title":"The relative roles of DNA damage induced by UVA irradiation in human cells","volume":"12","author":"Cortat","year":"2013","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib28","first-page":"3439","article-title":"Environmental skin cancer: mechanisms, models and human relevance","volume":"53","author":"Mukhtar","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/antiox4020248","article-title":"Mechanisms of photoaging and cutaneous photocarcinogenesis, and photoprotective strategies with phytochemicals","volume":"4","author":"Bosch","year":"2015","journal-title":"Antioxidants"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2012-101455","article-title":"Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants","volume":"50","author":"Puntervoll","year":"2013","journal-title":"J Med Genet"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7326\/0003-4819-102-4-458","article-title":"High risk of malignant melanoma in melanoma-prone families with dysplastic nevi","volume":"102","author":"Greene","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.seminoncol.2016.08.003","article-title":"Genetic predisposition to melanoma","volume":"43","author":"Hawkes","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10689-007-9166-4","article-title":"Pancreatic cancer and the FAMMM syndrome","volume":"7","author":"Lynch","year":"2008","journal-title":"Familial Cancer"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.08.038","article-title":"Hereditary melanoma: update on syndromes and management emerging melanoma cancer complexes and genetic counseling","volume":"74","author":"Soura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib35","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/0008-5472.CAN-18-1580","article-title":"Analysis of the CDKN2A gene in FAMMM syndrome families reveals early age of onset for additional syndromic cancers","volume":"79","author":"Middlebrooks","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib36","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1134\/S0006297918110019","article-title":"Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications","volume":"83","author":"Jiao","year":"2018","journal-title":"Biochemistry (Moscow)"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib37","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/sj.onc.1206461","article-title":"The INK4\u03b1\/ARF locus and melanoma","volume":"22","author":"Sharpless","year":"2003","journal-title":"Oncogene"},{"year":"2009","series-title":"Familial atypical multiple mole melanoma syndrome in cancer syndromes","author":"Eckerle Mize","key":"10.1016\/B978-0-12-818128-7.00013-7_bib38"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00403-001-0274-y","article-title":"Loss of p14ARF expression in melanoma","volume":"293","author":"Dobrowolski","year":"2002","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.sder.2010.06.002","article-title":"Genetic determinants of cutaneous melanoma predisposition","volume":"29","author":"Udayakumar","year":"2010","journal-title":"SemCutan Med Surg"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib41","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib43","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/107327480801500304","article-title":"Surgical management of melanoma in situ on chronically sun-damaged skin","volume":"15","author":"Clark","year":"2008","journal-title":"Cancer Control"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","article-title":"Chemotherapy for melanoma","volume":"167","author":"Wilson","year":"2016","journal-title":"Cancer Treat Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.clindermatol.2008.09.020","article-title":"Chemotherapy and biologic therapies for melanoma: do they work?","volume":"27","author":"Jilaveanu","year":"2009","journal-title":"Clin Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib47","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)08001-7","article-title":"Interferon alfa-2a for melanoma metastases [5]","volume":"359","author":"Kirkwood","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bjc.6600043","article-title":"Combination chemotherapy with or without s.c. IL-2 and IFN-\u03b1: results of a prospectively randomized trial of the cooperative advanced malignant melanoma chemoimmunotherapy group (ACIMM)","volume":"86","author":"Atzpodien","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib49","first-page":"CD011123","article-title":"Systemic treatments for metastatic cutaneous melanoma (Review)","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst Rev Syst"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40257-018-0389-y","article-title":"Mechanisms of resistance to immune checkpoint blockade","volume":"20","author":"Liu","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib51","doi-asserted-by":"crossref","first-page":"14612","DOI":"10.1002\/jcp.28181","article-title":"Immune therapy of melanoma: overview of therapeutic vaccines","volume":"234","author":"Payandeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib52","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CCO.0000000000000432","article-title":"Update on adjuvant melanoma therapy","volume":"30","author":"Dimitriou","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib54","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib55","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/1078-0432.CCR-14-3061","article-title":"Pembrolizumab for treatment of patients with advanced or unresectable melanoma","volume":"21","author":"Sullivan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib56","first-page":"180","article-title":"Opdivo (nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib57","first-page":"17","article-title":"Role of PD-1 in regulating T-cell immunity","volume":"350","author":"Jin","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib58","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib59","unstructured":"Five-year outcomes for opdivo (nivolumab) in combination with yervoy (ipilimumab) demonstrate durable long-term survival benefits in patients with advanced melanoma | BMS newsroom. Available from: <https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/five-year-outcomes-opdivo-nivolumab-combination-yervoy-ipilimu> [accessed 16.02.2020]."},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib60","first-page":"1","article-title":"An overview of targeted cancer therapy","volume":"5","author":"Padma","year":"2015","journal-title":"BioMedicine (Neth)"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib61","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib62","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd3579","article-title":"Vemurafenib","volume":"10","author":"Flaherty","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib64","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib65","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib66","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bcp.12651","article-title":"Vemurafenib\/dabrafenib and trametinib","volume":"80","author":"Rissmann","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib67","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF -mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib68","doi-asserted-by":"crossref","unstructured":"Saji Joseph J, Tebogo Malindisa S, Ntwasa M. Two-dimensional (2D) and three-dimensional (3D) cell culturing in drug discovery. London: IntechOpen; 2019. Available from: https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.023.","DOI":"10.5772\/intechopen.81552"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib69","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/exd.13670","article-title":"Progress in melanoma modelling in vitro","volume":"27","author":"Marconi","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib70","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/biot.200700228","article-title":"Recent advances in three-dimensional multicellular spheroid culture for biomedical research","volume":"3","author":"Lin","year":"2008","journal-title":"Biotechnol J"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib71","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jid.2016.05.116","article-title":"CD271 down-regulation promotes melanoma progression and invasion in three-dimensional models and in zebrafish","volume":"136","author":"Saltari","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib72","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/cddis.2013.249","article-title":"Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing","volume":"4","author":"V\u00f6 Rsmann","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib73","article-title":"A 3D organotypic melanoma spheroid skin model","volume":"2018","author":"M\u00fcller","year":"2018","journal-title":"J Vis Exp"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib74","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1136\/jcp.2005.025957","article-title":"Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma","volume":"58","author":"Zhuang","year":"2005","journal-title":"J Clin Pathol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib75","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1078-0432.CCR-07-1440","article-title":"The mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel","volume":"14","author":"Haass","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib76","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Therap Adv Med Oncol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib77","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1535-7163.MCT-15-0963","article-title":"Hypoxia-driven mechanism of vemurafenib resistance in melanoma","volume":"15","author":"Qin","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib78","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12885-019-5606-4","article-title":"A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells","volume":"19","author":"Klicks","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib79","doi-asserted-by":"crossref","unstructured":"Xiao J, Egger ME, Mcmasters KM, Hao H. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines. BMC Cancer 18, 2018, 675. Available from: https:\/\/doi.org\/10.1186\/s12885-018-4583-3.","DOI":"10.1186\/s12885-018-4583-3"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib80","first-page":"2937","article-title":"The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression","volume":"54","author":"Li","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0002-9440(10)64719-0","article-title":"Human melanoma progression in skin reconstructs biological significance of bFGF","volume":"156","author":"Meier","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib82","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/jid.2011.275","article-title":"Engineering melanoma progression in a humanized environment in vivo","volume":"132","author":"Kiowski","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib83","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1755-148X.2010.00763.x","article-title":"PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas","volume":"23","author":"Lee","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib84","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2353\/ajpath.2009.081057","article-title":"The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes","volume":"174","author":"Yu","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib85","first-page":"41","article-title":"Tumor necrosis factor related apoptosis inducing ligand inhibits the growth and aggressiveness of colon carcinoma via the exogenous apoptosis signaling pathway","volume":"17","author":"Gong","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib86","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1365-2133.2007.07821.x","article-title":"Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment","volume":"156","author":"Meier","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib87","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-15-0394","article-title":"A novel fully humanized 3D skin equivalent to model early melanoma invasion","volume":"14","author":"Hill","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/B978-0-12-818128-7.00013-7_bib88","doi-asserted-by":"crossref","first-page":"13191","DOI":"10.1038\/s41598-018-31502-6","article-title":"Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development","volume":"8","author":"Bourland","year":"2018","journal-title":"Sci Rep"}],"container-title":["Biomaterials for 3D Tumor Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128181287000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128181287000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T13:54:52Z","timestamp":1757685292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128181287000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128181287"],"references-count":88,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-818128-7.00013-7","relation":{},"subject":[],"published":{"date-parts":[[2020]]}}}